官方服务：
资源简介：
Analysis of the RNA-seq data in the TAMs from ICB non-responders compared to those from responders
应用场景：
创建时间：
2024-08-03
相关数据集
HCC Immunotherapy
We collected additional tumor tissues from the initial resection of two early-stage HCC patients for Stereo-seq. These patients were later put on immunotherapy with atezolizumab + bevacizumab after th
Figshare2023-09-23 更新40
Differential transcriptome responses in human THP-1 macrophages following exposure to T98G and LN-18 human glioblastoma secretions: a simplified bioinformatics approach to understanding patient-glioma-specific effects on tumor-associated macrophages
We first describe a methods approach to differentiating THP-1 monocytes to macrophages with M0-like genotype. Then we describe the effect that different glioblastoma supernatants have on the gene expr
NIAID Data Ecosystem20
Supplementary Material for: Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
Background: Preclinical models have shown that metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) may exhibit reduced responsiveness to immunothera
Figshare2025-05-24 更新10
Data_Sheet_1_Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.XLS
Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that pred
NIAID Data Ecosystem20
Supplementary Material for: Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma
Introduction: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (H
NIAID Data Ecosystem10
